Skip header and navigation

Refine By

28 records – page 1 of 3.

ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.

https://arctichealth.org/en/permalink/ahliterature78779
Source
Pharmacogenet Genomics. 2007 Feb;17(2):127-36
Publication Type
Article
Date
Feb-2007
Author
Nordgard Silje H
Ritchie Marylyn D
Jensrud Sigrid D
Motsinger Alison A
Alnaes Grethe I G
Lemmon Gordon
Berg Marianne
Geisler Stephanie
Moore Jason H
Lønning Per Eystein
Børresen-Dale Anne-Lise
Kristensen Vessela N
Author Affiliation
Department of Genetics, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
Source
Pharmacogenet Genomics. 2007 Feb;17(2):127-36
Date
Feb-2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Breast Neoplasms - drug therapy - enzymology - genetics
Case-Control Studies
Chi-Square Distribution
Doxorubicin - therapeutic use
Female
Genetic Predisposition to Disease
Genotype
Glutathione S-Transferase pi - genetics
Glutathione Transferase - genetics
Humans
Linkage Disequilibrium - genetics
Middle Aged
Mutation - genetics
Norway
Organic Anion Transporters - genetics
Polymorphism, Single Nucleotide - genetics
Recombination, Genetic
Treatment Outcome
Tumor Suppressor Protein p53 - genetics
Abstract
BACKGROUND AND OBJECTIVE: Many environmental and genetic factors influence the development of chemoresistance. The goal of this study was to characterize the genetic variation in the ABCB1, GSTM1, GSTT1 and GSTP1 genes, as well as the haplotype structure in the ABCB1 gene. METHODS: Variants in these genes were studied in 109 healthy controls and 93 breast cancer cases, both of Caucasian origin. The cases were analyzed in relation to TP53 mutation status and response to doxorubicin. Both single and multiple single nucleotide polymorphism analyses were performed. RESULTS: Chi-square analyses revealed a significant association between TP53 mutation status and both the GA genotype of ABCB1 exon 11 (Ser400Asn) and the GG genotype of GSTP1 (Ile105Val; P
PubMed ID
17301692 View in PubMed
Less detail

Adjuvant interferon treatment in human osteosarcoma.

https://arctichealth.org/en/permalink/ahliterature24246
Source
Cancer Treat Res. 1993;62:29-32
Publication Type
Article
Date
1993
Author
H. Strander
H C Bauer
O. Brosjö
A. Kreicbergs
J. Lindholm
U. Nilsonne
C. Silfverswärd
A. Szamosi
Source
Cancer Treat Res. 1993;62:29-32
Date
1993
Language
English
Publication Type
Article
Keywords
Biological Response Modifiers - therapeutic use
Bone Neoplasms - mortality - therapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Doxorubicin - therapeutic use
Follow-Up Studies
Humans
Interferon-alpha - therapeutic use
Methotrexate - therapeutic use
Neoplasm Recurrence, Local
Osteosarcoma - mortality - therapy
Research Support, Non-U.S. Gov't
Survival Rate
Abstract
An update of the adjuvant trial on osteosarcoma in Sweden comparing patients receiving natural interferon (IFN) alpha with a high-dose chemotherapy group and a nonadjuvant group is presented. The overall survival for the IFN group is 49%, for the chemotherapy group 54%, and for the nonadjuvant group 35%. Trial evaluation was complicated by group differences with respect to various clinicopathologic features of prognostic significance. The role of IFN in the treatment of osteosarcoma can still not be established.
PubMed ID
8096744 View in PubMed
Less detail
Source
Pediatr Akus Ginekol. 1973;1:53-5
Publication Type
Article
Date
1973

Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.

https://arctichealth.org/en/permalink/ahliterature21930
Source
Cancer Res. 1997 Oct 15;57(20):4530-6
Publication Type
Article
Date
Oct-15-1997
Author
H O Sjögren
M. Isaksson
D. Willner
I. Hellström
K E Hellström
P A Trail
Author Affiliation
Department of Cell and Molecular Biology, University of Lund, Sweden.
Source
Cancer Res. 1997 Oct 15;57(20):4530-6
Date
Oct-15-1997
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy - pathology - secondary
Animals
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Colonic Neoplasms - drug therapy - pathology
Doxorubicin - therapeutic use
Female
Humans
Immunotoxins - therapeutic use
Liver Neoplasms - drug therapy - pathology - secondary
Mice
Mice, Nude
Rats
Rats, Inbred BN
Research Support, Non-U.S. Gov't
Transplantation, Heterologous
Transplantation, Isogeneic
Tumor Cells, Cultured
Abstract
The internalizing monoclonal antibody BR96 was conjugated to the anticancer drug doxorubicin (DOX) using an acid-labile hydrazone bond to DOX and a thioether bond to the monoclonal antibody. The resulting conjugate, termed BR96-DOX, binds to a tumor-associated Lewis(y) antigen that is abundantly expressed on the surface of human carcinoma cells. BR96-DOX binds to RCA, a human colon carcinoma cell line, and BN7005, a transplantable colon carcinoma induced in a Brown Norway (BN) rat by 1,2-dimethyl-hydrazine. BR96-DOX produces cures of established s.c. RCA human colon carcinomas in athymic mice and rats. BR96-DOX also cured both s.c. and intrahepatic BN7005 tumors in immunocompetent BN rats. Unconjugated DOX, given at its maximum tolerated dose, and matching doses of nonbinding IgG-DOX conjugate were not active against RCA or BN7005 carcinomas. An anticonjugate antibody response was produced in BN rats treated with BR96-DOX. However, this could be largely prevented by administering the immunosuppressive drug deoxyspergualin. These results confirm the concept of antibody-directed therapy in models in which the targeted antigen is expressed both in normal tissues and tumors. The findings in BN7005 further demonstrate efficacy of BR96-DOX therapy in a model in which the tumor is syngeneic and the host is immunocompetent.
PubMed ID
9377565 View in PubMed
Less detail

Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.

https://arctichealth.org/en/permalink/ahliterature118594
Source
Histopathology. 2013 Jan;62(2):326-33
Publication Type
Article
Date
Jan-2013
Author
Siria Lemma
Peeter Karihtala
Kirsi-Maria Haapasaari
Esa Jantunen
Ylermi Soini
Risto Bloigu
Anna-Kaisa Pasanen
Taina Turpeenniemi-Hujanen
Outi Kuittinen
Author Affiliation
Department of Radiotherapy and Oncology, Oulu University Hospital, Oulu, Finland. slemma@mail.student.oulu.fi
Source
Histopathology. 2013 Jan;62(2):326-33
Date
Jan-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cell Nucleus - metabolism - pathology
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Epithelial-Mesenchymal Transition
Finland - epidemiology
Homeodomain Proteins - metabolism
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis - drug therapy - metabolism - mortality
Middle Aged
Neoplasm Staging
Nuclear Proteins - metabolism
Prednisone - therapeutic use
Prognosis
Survival Rate
Transcription Factors - metabolism
Tumor Markers, Biological - metabolism
Twist Transcription Factor - metabolism
Vincristine - therapeutic use
Young Adult
Abstract
To evaluate the biological roles and prognostic significance of the epithelial-mesenchymal transition (EMT)-mediating transcription factors (TFs) Twist, ZEB1 and Slug in patients with diffuse large B-cell lymphoma (DLBCL). EMT has been shown to enhance solid tumour metastasis, invasion, and proliferation.
Expression of Twist, ZEB1 and Slug was evaluated immunohistochemically in eight samples from reactive lymphoid tissues and in diagnostic samples from 102 DLBCL patients treated with curative intent with R-CHOP-type chemotherapy. ZEB1 and Slug expression correlated with adverse disease presentation. However, cytoplasmic Slug expression was linked to a favourable disease outcome, whereas nuclear expression of ZEB1 indicated an adverse outcome.
This study shows that an EMT-like process occurs in lymphomas. Of the TFs investigated, ZEB1 seems to be the main one associated with adverse clinical presentation and clinical outcome. Surprisingly, Slug expression in cytoplasm was linked to a favourable prognosis. Further studies are needed to evaluate whether inhibition of ZEB1 could serve as a therapeutic target.
PubMed ID
23190132 View in PubMed
Less detail

Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience.

https://arctichealth.org/en/permalink/ahliterature229478
Source
J Clin Oncol. 1990 Mar;8(3):538-47
Publication Type
Article
Date
Mar-1990
Author
T A Alvegard
N O Berg
B. Baldetorp
M. Fernö
D. Killander
J. Ranstam
A. Rydholm
M. Akerman
Author Affiliation
Department of Oncology, Lund University Hospital, Sweden.
Source
J Clin Oncol. 1990 Mar;8(3):538-47
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Combined Modality Therapy
DNA, Neoplasm - analysis
Doxorubicin - therapeutic use
Female
Flow Cytometry
Humans
Male
Middle Aged
Prognosis
Prospective Studies
Randomized Controlled Trials as Topic
Risk factors
Sarcoma - analysis - mortality - pathology - therapy
Scandinavia - epidemiology
Soft Tissue Neoplasms - analysis - mortality - pathology - therapy
Abstract
The nuclear DNA content of 148 high-grade soft tissue sarcomas of the extremities and trunk was determined by flow cytometry, using tumor material from paraffin-embedded tissue. The patients were part of a prospective randomized clinical trial on the efficacy of adjuvant single-agent chemotherapy with doxorubicin. Chemotherapy did not improve the metastasis-free survival (MFS). After a median follow-up time of 48 months (range, 2 to 97), a multivariate analysis of prognostic factors for developing metastatic disease was performed. DNA aneuploidy was found to be an independent prognostic risk factor in addition to histologic malignancy grade IV, intratumoral vascular invasion, tumor size over 10 cm, and male sex. Patients with none or one risk factor had a 5-year MFS of 79%, with two risk factors 65%, with three risk factors 43%, and with four and five risk factors 0%. About one half (78 of 148) of the patients with three factors or less belonged to a group with a MFS over 60%. The combination of different risk factors, including DNA aneuploidy, seems to be a useful prognostic model for soft tissue sarcomas, which could be of value to select high-risk patients for further trials with adjunctive therapy.
PubMed ID
2407813 View in PubMed
Less detail

Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.

https://arctichealth.org/en/permalink/ahliterature266649
Source
Blood. 2015 Jul 2;126(1):36-41
Publication Type
Article
Date
Jul-2-2015
Author
Fredrik Ellin
Jenny Landström
Mats Jerkeman
Thomas Relander
Source
Blood. 2015 Jul 2;126(1):36-41
Date
Jul-2-2015
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Central Nervous System Neoplasms - drug therapy - epidemiology - secondary
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Etoposide - therapeutic use
Female
Hematopoietic Stem Cell Transplantation - statistics & numerical data
Humans
Lymphoma, T-Cell, Peripheral - drug therapy - epidemiology - pathology
Male
Middle Aged
Prednisolone - therapeutic use
Prednisone - therapeutic use
Recurrence
Registries
Sweden - epidemiology
Vincristine - therapeutic use
Abstract
Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis. Risk factors and outcome have been studied in aggressive B-cell lymphomas, but very little is known about the risk in peripheral T-cell lymphoma (PTCL). We aimed at analyzing risk factors for CNS involvement at first relapse or progression, as well as the outcome of these patients, in a large population-based cohort of patients with PTCL. Twenty-eight out of 625 patients (4.5%) developed CNS disease over time. In multivariable analysis, disease characteristics at diagnosis independently associated with an increased risk for later CNS involvement were involvement of more than 1 extranodal site (hazard ratio [HR], 2.60; 95% confidence interval [CI], 1.07-6.29; P = .035) and skin (HR, 3.51; 95% CI, 1.26-9.74; P = .016) and gastrointestinal involvement (HR, 3.06; 95% CI, 1.30-7.18; P = .010). The outcome of relapsed/refractory patients was very poor, and CNS involvement was not associated with a significantly worse outcome compared with relapsed/refractory patients without CNS involvement in multivariable analysis (HR, 1.6; 95% CI, 0.96-2.6; P = .074). The results from the present study indicate that CNS relapse in PTCL occurs at a frequency similar to what is seen in aggressive B-cell lymphomas, but the poor outcomes in relapse are largely driven by systemic rather than CNS disease.
PubMed ID
25957393 View in PubMed
Less detail

Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.

https://arctichealth.org/en/permalink/ahliterature201278
Source
Acta Orthop Scand Suppl. 1999 Jun;285:62-8
Publication Type
Article
Date
Jun-1999
Author
J O Fernberg
T. Wiklund
O. Monge
K S Hall
G. Saeter
T A Alvegård
H. Strander
Author Affiliation
Dept. of Oncology, Karolinska Hospital, Stockholm, Sweden.
Source
Acta Orthop Scand Suppl. 1999 Jun;285:62-8
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Adult
Antineoplastic Agents - therapeutic use
Antineoplastic Agents, Alkylating - therapeutic use
Antineoplastic Agents, Phytogenic - therapeutic use
Chemotherapy, Adjuvant
Disease-Free Survival
Doxorubicin - therapeutic use
Etoposide - therapeutic use
Humans
Ifosfamide - therapeutic use
Prognosis
Registries
Remission Induction
Risk factors
Sarcoma - drug therapy - mortality - surgery
Scandinavia
Soft Tissue Neoplasms - drug therapy - mortality - surgery
Treatment Outcome
Abstract
The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I). It evaluated the single agent adjuvant doxorubicin in a randomized setting in patients with high-grade STS. No improvement was noted in the overall survival or disease-free survival rate. More intense chemotherapy was thereafter (1991-1994) evaluated in a phase 2 study, introducing ifosfamide and a continuous infusion of etoposide with growth factor (SSG X). The response rate of previously untreated patients was high (42%), but complete remissions were few. Analysis of patients undergoing surgery after preoperative chemotherapy suggested an increased survival. A recent meta-analysis of adjuvant chemotherapy for localized resectable STS in adults, including the SSG I trial, indicated a better disease-free survival and possibly improved overall survival (Thierny et al. 1997). At present, we are studying whether such a benefit can be shown in patients with high-risk prognostic criteria by giving adjuvant ifosfamide and doxorubicin treatment after primary surgery (SSG XIII). In the latter SSG study, started on July 1, 1998, the adjuvant therapy is evaluated in a phase 2 study in selected patients with high-grade STS and other unfavorable prognostic factors.
PubMed ID
10429625 View in PubMed
Less detail

A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.

https://arctichealth.org/en/permalink/ahliterature167200
Source
Ann Oncol. 2007 Jan;18(1):129-35
Publication Type
Article
Date
Jan-2007
Author
K M Ramadan
T. Shenkier
L H Sehn
R D Gascoyne
J M Connors
Author Affiliation
Division of Hematology, British Columbia Cancer Agency, Vancouver, Canada.
Source
Ann Oncol. 2007 Jan;18(1):129-35
Date
Jan-2007
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Neoplasms - epidemiology - pathology - therapy
British Columbia - epidemiology
Cohort Studies
Combined Modality Therapy
Cyclophosphamide - therapeutic use
Disease-Free Survival
Doxorubicin - therapeutic use
Female
Humans
Lymphoma, Large B-Cell, Diffuse - epidemiology - pathology - therapy
Male
Medical Records
Middle Aged
Prednisone - therapeutic use
Prognosis
Radiotherapy
Retrospective Studies
Vincristine - therapeutic use
Abstract
Primary bone lymphoma (PBL) is a distinct clinicopathological entity. Although PBL has been reviewed in several small studies, few reflect recent improvements in primary treatment.
We used the British Columbia Cancer Agency Lymphoid Cancer Database to identify all patients with PBL (1983-2005). All were staged in a uniform manner and treated with era-specific protocols.
We identified 131 patients with a median age of 63 years (18-87). One third had disease in long bones and another one third had disease in the spine, of which half presented with spinal cord compression. Patients with diffuse large-cell lymphoma (DLCL) (n=103, 79%) had 5- and 10-year overall survivals (OS) of 62% and 41%, respectively. Multivariate analysis identified three prognostic groups: ageor=60 with IPI 0-3 (n=23) and age>or=60 with IPI 4-5 (n=33), with markedly different 5-year OS of 90%, 61% and 25%, respectively (P
PubMed ID
17018705 View in PubMed
Less detail

28 records – page 1 of 3.